Purchase this article with an account.
M. K. Gemenetzi, A. Luff, A. J. Lotery; Successful Treatment of Choroidal Neovascularization Secondary to Sorsby’s Fundus Dystrophy With Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2821.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the response of choroidal neovascularization (CNV) in Sorsby’s fundus dystrophy (SFD) to intravitreal bevacizumab.
Three eyes of two patients with choroidal neovascularization due to Sorsby’s fundus dystrophy were treated with intravitreal bevacizumab injections (0.05ml, 1.25mg of bevacizumab). Best corrected visual acuity (BCVA), optical coherence tomography (OCT) or/and fluorescein angiography (FA) prior to and following treatment were assessed.
At 33 months follow-up, after six intravitreal bevacizumab injections in one eye of the first patient, BCVA improved from 1.00 to 0.93 logMAR; there was no evidence of CNV activity on OCT and on FA. At six weeks after one injection in the first patient’s fellow eye, BCVA was stabilized at 0.00 logMAR without any CNV activity on OCT and FA. At 12 weeks follow-up, after one intravitreal bevacizumab injection in one eye of the second patient, BCVA improved from 1.00 to 0.00 logMAR; there was no evidence of CNV activity on OCT and on FA.
Intravitreal bevacizumab should be considered as a safe and effective treatment for CNV secondary to SFD.
This PDF is available to Subscribers Only